2024-03-29T12:31:04Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/48102022-12-01T17:49:54Zcom_20.500.12105_2060com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2061
Repisalud
author
Domingo Carrasco, Cristina
author
Alves, María Joao
author
De Ory, Fernando de
author
Teichmann, Anette
author
Schmitz, Herbert
author
Müller, Rolf
author
Niedrig, Matthias
2017-09-04T16:28:03Z
2017-09-04T16:28:03Z
2015-04-01
BMC Infect Dis. 2015; 15: 167
http://hdl.handle.net/20.500.12105/4810
25886961
10.1186/s12879-015-0877-0
1471-2334
BMC Infectious Diseases
BACKGROUND: Dengue is endemic to the tropics and subtropics, and the most frequent of arthropod-borne viral diseases. Reliable diagnosis of dengue infection is important not only in clinical care but also in disease surveillance, the control of outbreaks, and the development of new vaccines. The diagnosis of dengue infection is usually established by a variety of commercial or in-house serological protocols. The European Network for the Diagnostics of Imported Viral Diseases (ENIVD) recognized the need to survey the accuracy of dengue serological diagnostics in current use, and organized an external quality assurance (EQA) study of dengue serological practice in diagnostic laboratories. METHODS: A 15-sample panel, consisting of sera reactive against dengue plus specificity and negative controls, was sent to 48 laboratories for serological testing. The results returned by the participating laboratories were anonymized, scored, and subjected to comparison and statistical analysis. RESULTS: Ten laboratories rated all samples correctly with regard to IgM, and only three achieved the full score for IgG detection. The main handicaps in assay performance were suboptimal sensitivity of in-house IgM detection protocols by comparison with better-performing commercial ELISA tests, and the presence of IgG cross-reactivity with heterologous flaviviruses. Differences of detail in the methodology of dengue IgG antibody detection appear to underlie the disparities in accuracy observed between laboratories. CONCLUSION: This EQA study demonstrates that there is room for many laboratories to improve sensitivity in the detection of anti-dengue virus IgM antibodies, against the benchmark set by commercial antibody capture ELISA tests. The EQA shows also that cross-reactivity is a continuing issue, and IgG detection protocols must be optimized to increase their specificity.
eng
Dengue
Serology
External quality assessment
Dengue IgM
Dengue IgG
International external quality control assessment for the serological diagnosis of dengue infections
journal article
URL
https://repisalud.isciii.es/bitstream/20.500.12105/4810/1/InternationalExternalQualityControl_2015.pdf
File
MD5
edaf03c4cd152f7904c04819b107a6c8
454178
application/pdf
InternationalExternalQualityControl_2015.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/4810/20/12879_2015_Article_877.pdf.txt
File
MD5
6031e04d4f0803a86a39252144046b2b
41693
text/plain
12879_2015_Article_877.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/4810/22/InternationalExternalQualityControl_2015.pdf.txt
File
MD5
6031e04d4f0803a86a39252144046b2b
41693
text/plain
InternationalExternalQualityControl_2015.pdf.txt
URL
https://repisalud.isciii.es/bitstream/20.500.12105/4810/26/InternationalExternalQualityControl_2015.pdf.txt
File
MD5
c24bd4a7516f302c6d3b521cb252973e
41670
text/plain
InternationalExternalQualityControl_2015.pdf.txt